UTSW Medical Center Trials

UTSW Medical Center	Welcome, Profile Billing Logout

59 Trials

Active Trials Industry lead sponsorIndustry collaborator

Export

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Dowell, Jonathan E

SWOG S2302, NCT05633602: Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

Recruiting

700

Chemotherapy, Chemo, Chemotherapy (NOS), Chemotherapy, Cancer, General, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Ramucirumab, Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B, Cyramza, IMC-1121B, LY3009806

SWOG Cancer Research Network, National Cancer Institute (NCI), Eli Lilly and Company, Merck Sharp & Dohme LLC

Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8

01/27

03/28

DREAM3R, NCT04334759: DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma

Active, not recruiting

214

US, RoW

Durvalumab, MEDI4736, Imfinzi, Standard Chemotherapy, Cisplatin or Carboplatin and Pemetrexed, Ipilimumab and Nivolumab, Yervoy, Opdivo

PrECOG, LLC., AstraZeneca, Thoracic Oncology Group Australasia (TOGA), University of Sydney

Mesothelioma, Pleural Mesothelioma, Malignant Pleural Mesothelioma

06/25

02/26

HARMONIC, NCT05456256: A Study of LP-300 with Carboplatin and Pemetrexed in Never Smokers with Advanced Lung Adenocarcinoma

Recruiting

Japan, US, RoW

LP-300, Tavocept, BNP7787, Dimesna, Pemetrexed, Alimta, Pemfexy, Carboplatin, Paraplatin

Lantern Pharma Inc.

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

12/25

06/26

RAMP 203, NCT05074810: Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients

Recruiting

1/2

153

Europe, US

avutometinib and sotorasib, AMG 510, LUMAKRAS™, VS-6766, avutometinib and sotorasib and defactinib, VS-6063

Verastem, Inc., Amgen

Non Small Cell Lung Cancer, KRAS Activating Mutation

09/25

04/27

Jain, Mamta K

RESOLUTION, NCT04417257: Study of LAU-7b for the Treatment of COVID-19 Disease in Adults

Completed

2/3

125

Canada, US

LAU-7b, fenretinide, Placebo oral capsule

Laurent Pharmaceuticals Inc.

COVID-19 Disease

02/24

05/24

NCT03993106 / 2017-001828-22: A Study of sEphB4-HSA in Kaposi Sarcoma

Recruiting

sEphB4-HSA

Vasgene Therapeutics, Inc

Kaposi Sarcoma

12/24

06/25

Gruber, Joshua S

NCT05082610: A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors

Active, not recruiting

313

HMBD-002, Pembrolizumab

Hummingbird Bioscience, Merck Sharp & Dohme LLC

Cancer, Tumor, Solid, Nonsmall Cell Lung Cancer, Triple Negative Breast Cancer, Malignant Neoplasm, Metastatic Cancer, Advanced Solid Tumor

11/24

07/25

Smith, Carrie

NCT03926624: Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage

Recruiting

450

DFP-10917, Cytarabine, Azacitidine, Decitabine, Mitoxantrone, Etoposide, Fludarabine, Idarubicin, Venetoclax, Cladribine

Delta-Fly Pharma, Inc.

Leukemia, Myeloid, Acute

12/25

06/26

NCT03671044: A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients

Recruiting

657

US, RoW

Nanosomal Docetaxel Lipid Suspension (75 mg/m2), Nanosomal Docetaxel Lipid Suspension (100 mg/m2), Taxotere® (100 mg/m2)

Jina Pharmaceuticals Inc., Intas Pharmaceuticals, Ltd., Lambda Therapeutic Research Ltd.

Triple Negative Breast Cancer

05/25

12/25

NCT01954992: Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer

Recruiting

480

Glufosfamide, Fluorouracil, 5-FU

Eleison Pharmaceuticals LLC.

Metastatic Pancreatic Adenocarcinoma

06/26

12/26

BRIA-ABC, NCT06072612: Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

Recruiting

404

SV-BR-1-GM, Part of the Bria-IMT regimen, Cyclophosphamide, Interferon infiltration of the inoculation site, Retifanlimab, Treatment of Physician's Choice

BriaCell Therapeutics Corporation

Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm, Breast Cancer Metastatic, End Stage Cancer

01/26

06/26

NCT03899467: The Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPC

Completed

GT0918, proxalutamide, androgen receptor antagonist

Suzhou Kintor Pharmaceutical Inc,

Metastatic Castrate Resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

03/22

09/22

NCT06246110: A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC

Recruiting

EIK1001, Pembrolizumab, Paclitaxel, Pemetrexed, Carboplatin

Eikon Therapeutics

NSCLC

12/26

12/27

SGNLVA-005, NCT04032704 / 2019-001946-17: A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

Terminated

205

Europe, US, RoW

ladiratuzumab vedotin, SGN-LIV1A, pembrolizumab, Keytruda

Seagen Inc., Merck Sharp & Dohme LLC

Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous, Non-small Cell Lung Cancer, Non-squamous, Head and Neck Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Prostate Cancer, Melanoma

11/23

KEYNOTE B36, NCT04892472: EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer

Terminated

NovoTTF-200T, Pembrolizumab (MK-3475) 200 mg

NovoCure GmbH, Merck Sharp & Dohme LLC

Non-small Cell Lung Cancer

01/25

VIRO-25, NCT06463665: Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer

Recruiting

142

Olvimulogene nanivacirepvec, Olvi-Vec, GL-ONC, GLV-1h68, Platinum chemotherapy: carboplatin or cisplatin, Brand of drug is based on institutional procurement, Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC, Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumab, Docetaxel

Genelux Corporation, Newsoara Biopharma Co., Ltd.

Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Squamous Non-Small Cell Lung Carcinoma, Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage III, Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Recurrent

02/27

07/29

NCT06568692: A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer

Recruiting

PCS6422 and capecitabine, Capecitabine

Processa Pharmaceuticals

Breast Cancer, TNBC - Triple-Negative Breast Cancer, HER2-negative Breast Cancer

09/26

10/26

HARMONIC, NCT05456256: A Study of LP-300 with Carboplatin and Pemetrexed in Never Smokers with Advanced Lung Adenocarcinoma

Recruiting

Japan, US, RoW

LP-300, Tavocept, BNP7787, Dimesna, Pemetrexed, Alimta, Pemfexy, Carboplatin, Paraplatin

Lantern Pharma Inc.

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

12/25

06/26

A2A-005, NCT05403385: Study of Inupadenant (EOS100850) with Chemotherapy As Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer

Recruiting

186

Europe, Canada, US, RoW

inupadenant, EOS100850, Placebo, Carboplatin, Pemetrexed, Alimta

iTeos Therapeutics, iTeos Belgium SA

Metastatic NSCLC - Non-Small Cell Lung Cancer, Locally Advanced NSCLC - Non-Small Cell Lung Cancer

04/25

05/25

NCT05494697: Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC

Jan 2024 - Dec 2024 : Data readout for locally advanced pancreatic adenocarcinoma

Suspended

Rintatolimod, Ampligen, poly I : poly C12U

AIM ImmunoTech Inc., Amarex Clinical Research

Pancreatic Cancer

09/28

10/28

AVB500-PC-005, NCT04983407: Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic Adenocarcinoma

Terminated

1b/2

batiraxcept, AVB-S6-500, Nab paclitaxel, Abraxane, Gemcitabine

Aravive, Inc.

Pancreatic Adenocarcinoma

08/23

NCT05320198: Study of DISC-0974 in Participants with Myelofibrosis or Myelodysplastic Syndrome and Anemia

Recruiting

1/2

150

DISC-0974

Disc Medicine, Inc

Myelofibrosis; Anemia, Anemia, Myelofibrosis, Myelofibrosis Due to and Following Polycythemia Vera, Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Myelodysplastic Syndromes

09/26

INDP-D101, NCT05651022: Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors

Recruiting

1/2

120

Decoy20, Tislelizumab

Indaptus Therapeutics, Inc, Translational Drug Development

Solid Tumor, Adult, HCC - Hepatocellular Carcinoma, CRC (Colorectal Cancer), Pancreatic Adenocarcinoma, NSCLC Non-small Cell Lung Cancer, Squamous Cell Cancer of the Head and Neck, UC (Urothelial Cancer), MSI-H Cancer

06/27

09/27

INX-315-01, NCT05735080: Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

Recruiting

1/2

150

US, RoW

INX-315, Fulvestrant, faslodex, Abemaciclib, Verzenio

Incyclix Bio

Breast Cancer, Breast Cancer Metastatic, Hormone Receptor Positive Tumor, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Ovarian Cancer, CCNE1 Amplification, Solid Tumor, Advanced Cancer, Metastatic Cancer

12/25

06/26

XTX301-01, NCT05684965: XTX301 in Patients with Advanced Solid Tumors

Recruiting

1/2

358

XTX301

Xilio Development, Inc.

Advanced Solid Tumor

02/27

NCT05622058: A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer

Terminated

Europe, US, RoW

ALRN-6924, TAC (doxorubicin 50 mg/m2; cyclophosphamide 500 mg/m2; docetaxel 75 mg/m2)

Aileron Therapeutics, Inc.

Prevention of Chemotherapy-induced Myelosuppression

02/23

NCT04215809 / 2020-002736-73: Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL

Recruiting

144

US, RoW

Lisaftoclax

Ascentage Pharma Group Inc.

CLL/SLL

10/25

06/27

KEYNOTE-A78, NCT03978689: A Phase 1 Study in Patients with HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma

Active, not recruiting

CUE-101, KEYTRUDA®, Pembrolizumab, Pembrolizumab

Cue Biopharma, Merck Sharp & Dohme LLC

Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Related Carcinoma

01/26

NCT04958434: Study of TST005 in Patients With Locally Advanced or Metastatic Solid Tumors

Terminated

TST005

Suzhou Transcenta Therapeutics Co., Ltd.

Locally Advanced or Metastatic Cancers, Metastatic Human Papillomavirus-Related Malignant Neoplasm

09/23

NCT06130722: First-in-Human, Phase I, Open-label, Multicenter, Dose Escalation Clinical Study

Recruiting

FL115

Suzhou Forlong Biotechnology Co.,Ltd,

Locally Advanced/Metastatic Solid Tumors

05/25

09/25

IO-108-CL-001, NCT05054348: First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors

Completed

IO-108, IO-108 + pembrolizumab combination therapy, IO-108 + Keytruda combination therapy, IO-108 + cemiplimab combination therapy, IO-108 + Libtayo combination therapy

Immune-Onc Therapeutics, Regeneron Pharmaceuticals

Solid Tumor, Adult

04/24

05/24

NKT3447-101, NCT06264921: A Study with NKT3447 for Adults with Advanced/Metastatic Solid Tumors

Active, not recruiting

NKT3447

NiKang Therapeutics, Inc.

Solid Tumor, Solid Tumor, Adult, Advanced Solid Tumor, Metastatic Tumor, Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Metastatic Ovarian Carcinoma, Endometrial Cancer, Endometrial Neoplasms, Endometrial Diseases, Metastatic Endometrial Cancer, Metastatic Endometrial Carcinoma, Advanced Endometrial Carcinoma, Advanced Ovarian Carcinoma, Gastric Cancer, Advanced Gastric Carcinoma, Metastatic Gastric Cancer, Metastatic Gastric Carcinoma, Small-cell Lung Cancer, Small Cell Lung Carcinoma, Triple Negative Breast Cancer, Triple Negative Breast Neoplasms, Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Carcinoma, CCNE1 Amplification, Hormone Receptor Negative Breast Carcinoma, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Progesterone-receptor-positive Breast Cancer

11/25

03/27

NCT05600582: A Study of CodaLytic, an Intratumoral Oncolytic Virus, in Patients With Breast Cancer

Withdrawn

CodaLytic

Codagenix, Inc

Breast Neoplasms, Neoplasm Metastasis

09/24

01/25

NCT03556228: Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

Recruiting

VMD-928 300 mg Tablet (ongoing); 100 mg Capsule (complete)

VM Oncology, LLC

Head and Neck Carcinoma, Adenoid Cystic Carcinoma, Lung Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Pancreatic Cancer, Mesothelioma, Thymic Carcinoma, Cervical Cancer, Ovarian Cancer, Bladder Cancer, Esophageal Cancer, Uterine Cancer, Sarcoma, Any Solid Tumors Progressed After a Prior Immunotherapy, Thymoma, Appendiceal Cancer, Olfactory Neuroblastoma

07/26

12/26

CUE-102-01, NCT05360680: A Phase 1 in Patients with HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers

Completed

CUE-102

Cue Biopharma

Colorectal Cancer, Gastric Cancer, Pancreatic Cancer, Ovarian Cancer

03/25

NCT05293912: SG2501 Safety Study in Subjects with Relapsed or Refractory Hematological Malignancies and Lymphoma.

Terminated

SG2501, Recombinant Anti-cluster of Differentiation 38(CD38)/47(CD47) Bispecific Antibody

Hangzhou Sumgen Biotech Co., Ltd.

Hematological Malignancy, Lymphoma

06/23

SGR-1505-101, NCT05544019: Study of SGR-1505 in Mature B-Cell Neoplasms

Recruiting

US, RoW

SGR-1505

Schrödinger, Inc.

Mature B-Cell Neoplasm, Non Hodgkin Lymphoma, DLBCL, Waldenstrom Macroglobulinemia, MALT Lymphoma, Follicular Lymphoma, Pediatric-Type Follicular Lymphoma, IRF4 Gene Rearrangement, EBV-Positive DLBCL, Nos, Burkitt Lymphoma, Plasmablastic Lymphoma, High-grade B-cell Lymphoma, Primary Cutaneous Follicle Center Lymphoma, Primary Effusion Lymphoma, Mantle Cell Lymphoma, DLBCL Germinal Center B-Cell Type, Primary Mediastinal Large B Cell Lymphoma, T-Cell/Histiocyte Rich Lymphoma, ALK-Positive Large B-Cell Lymphoma, Primary Cutaneous Diffuse Large B-Cell Lymphoma, Splenic Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, Nodal Marginal Zone Lymphoma, HHV8-Positive DLBCL, Nos, Lymphoplasmacytic Lymphoma, Duodenal-Type Follicular Lymphoma

03/26

NCT05627063: A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors

Recruiting

169

US, RoW

ABSK121-NX

Abbisko Therapeutics Co, Ltd

Solid Tumor

03/25

06/25

NCT05757492: Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors

Terminated

CHS-006 (anti-TIGIT), JS006, toripalimab (anti-PD-1), CHS-007, TAB001, JS001

Coherus Biosciences, Inc., Medpace, Inc., Shanghai Junshi Bioscience Co., Ltd.

Advanced Solid Tumor, Non-Small Cell Lung Cancer, Hepatocellular Carcinoma

07/24

ON-5001, NCT06022029: A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

Recruiting

168

US, RoW

ONM-501, Cemiplimab, Libtayo

OncoNano Medicine, Inc.

Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Lymphoma, Non-Hodgkin, Mantle Cell Lymphoma, Bladder Cancer, Uveal Melanoma, Recurrent, Cervix Cancer, Carcinoma in Situ, Head and Neck Squamous Cell Carcinoma, Skin Cancer, Metastatic Cancer, Tumor, Solid, Tumor Recurrence

04/26

08/26

IGM-8444-001, NCT04553692: Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers

Terminated

272

Europe, US, RoW

Aplitabart (IGM-8444), FOLFIRI, Fluorouracil or 5-FU, Leucovorin, Irinotecan, Bevacizumab (and approved biosimilars), Avastin, Birinapant, Venetoclax, Venclexta, Gemcitabine, Gemzar, Docetaxel, Taxotere, Docefrez, Azacitidine, VIDAZA

IGM Biosciences, Inc.

Solid Tumor, Colorectal Cancer, Non Hodgkin Lymphoma, Sarcoma, Chondrosarcoma, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia

01/25

ELEPHAS-01, NCT05478538: Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform

Recruiting

N/A

200

Core Needle or Forceps Biopsy

Elephas, Beaufort CRO

Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer, NSCLC, Metastatic NSCLC - Non-Small Cell Lung Cancer

12/26

Creo, Ana L

HAMS-AB-01B, NCT06057454: R-5280 in Newly Diagnosed Patients with Type 1 Diabetes

Recruiting

R-5280, Placebo

Rise Therapeutics LLC

Type 1 Diabetes, Type 1 Diabetes (Juvenile Onset), Diabetes Mellitus, Type 1

05/25

09/25

palma, Ingrid

CBX-12-101, NCT04902872: Study of CBX-12 in Subjects with Advanced or Metastatic Refractory Solid Tumors

Active, not recruiting

1/2

130

CBX-12

Cybrexa Therapeutics

Solid Tumor, Adult, Epithelial Ovarian Cancer, Small Cell Lung Carcinoma, Breast Cancer, Colorectal Cancer, Pancreas Cancer, Appendix Cancer, Non-small Cell Lung Cancer, Gastric Cancer, Esophagus Cancer, Urothelial Carcinoma, Sarcoma

03/25

06/25

KEYNOTE-B47, NCT04130516: Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and with Pembrolizumab

Recruiting

1/2

200

LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER, Pembrolizumab - anti-PD-1 antibody, KEYTRUDA®, Pembrolizumab

Linnaeus Therapeutics, Inc., Merck Sharp & Dohme LLC

Solid Tumor, Adult

12/26

12/27

NCT04875806: A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors

Terminated

1/2

NC762

NextCure, Inc.

Advanced or Metastatic Solid Tumors, Ovarian Cancer, Non-small Cell Lung Cancer, Breast Cancer

01/24

ABOYA-119, NCT04905914: Study Of ATRN-119 In Patients With Advanced Solid Tumors

Recruiting

1/2

132

ATRN-119

Aprea Therapeutics

Advanced Solid Tumor

02/28

NCT05902988: A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

Recruiting

1/2

120

VLS-1488

Volastra Therapeutics, Inc.

Advanced Solid Tumor, High Grade Serous Adenocarcinoma of Ovary, Squamous Non-small-cell Lung Cancer, Triple Negative Breast Cancer, Gastric Adenocarcinoma, Colorectal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Transitional Cell Carcinoma of Bladder, Head and Neck Squamous Cell Carcinoma, Ovarian Carcinosarcoma, Uterine Carcinosarcoma, Uterine Serous Carcinoma, Endometrium Cancer, Chromosomal Instability

12/25

06/26

ACR-368-201, NCT05548296: A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma

Recruiting

1/2

390

ACR-368, prexasertib, Gemcitabine, OncoSignature

Acrivon Therapeutics, GOG Foundation

Platinum-resistant Ovarian Cancer, Endometrial Adenocarcinoma, Urothelial Carcinoma

07/26

12/27

NCT04717375: Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors

Active, not recruiting

1/2

456

Europe, Canada, US, RoW

SAR444881, BND-22, Pembrolizumab, Cetuximab, Carboplatin, Pemetrexed

Sanofi

Cancer, Neoplasm

06/25

NCT04237649: KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors

Terminated

Europe, Canada, Japan, US, RoW

KAZ954, PDR001, NIR178, NZV930

Novartis Pharmaceuticals

Solid Tumors

09/23

QTX3034-001, NCT06227377: QTX3034 in Patients With KRAS G12D Mutation

Recruiting

250

QTX3034, Cetuximab

Quanta Therapeutics

Solid Tumors

04/27

NCT05082610: A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors

Active, not recruiting

313

HMBD-002, Pembrolizumab

Hummingbird Bioscience, Merck Sharp & Dohme LLC

Cancer, Tumor, Solid, Nonsmall Cell Lung Cancer, Triple Negative Breast Cancer, Malignant Neoplasm, Metastatic Cancer, Advanced Solid Tumor

11/24

07/25

CPO-100-US-101, NCT04931823: Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors

Active, not recruiting

126

CPO-100, DTX-HSA

Conjupro Biotherapeutics, Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Solid Tumor

03/25

KEYNOTE-F86, NCT05787587: A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

Recruiting

216

IDE-161, Pembrolizumab, KEYTRUDA®

IDEAYA Biosciences, Merck Sharp & Dohme LLC

Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer, Endometrial Cancer, Colorectal Cancer, Head and Neck Cancers, Nsclc

10/26

05/27

NCT05702424: Evaluation of IGM-7354 in Adults With Relapsed and/or Refractory Cancer

Completed

IGM-7354

IGM Biosciences, Inc.

Solid Tumor

05/24

NCT05753722: A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies

Recruiting

270

PRTH-101, Pembrolizumab

Incendia Therapeutics

Advanced or Metastatic Solid Tumors

09/27

ELVCAP-002-01, NCT05980416: Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2

Recruiting

120

Japan, US, RoW

EO-3021

Elevation Oncology

Pancreas Neoplasm, Stomach Neoplasm, Gastrointestinal Neoplasms, Digestive System Neoplasm, Neoplasms by Site, Neoplasms

09/28

12/28

Brinkman, Janet

HAMS-AB-01B, NCT06057454: R-5280 in Newly Diagnosed Patients with Type 1 Diabetes

Recruiting

R-5280, Placebo

Rise Therapeutics LLC

Type 1 Diabetes, Type 1 Diabetes (Juvenile Onset), Diabetes Mellitus, Type 1

05/25

09/25

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Dowell, Jonathan E

SWOG S2302, NCT05633602: Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

Recruiting

700

SWOG Cancer Research Network, National Cancer Institute (NCI), Eli Lilly and Company, Merck Sharp & Dohme LLC

Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8

01/27

03/28

DREAM3R, NCT04334759: DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma

Active, not recruiting

214

US, RoW

Durvalumab, MEDI4736, Imfinzi, Standard Chemotherapy, Cisplatin or Carboplatin and Pemetrexed, Ipilimumab and Nivolumab, Yervoy, Opdivo

PrECOG, LLC., AstraZeneca, Thoracic Oncology Group Australasia (TOGA), University of Sydney

Mesothelioma, Pleural Mesothelioma, Malignant Pleural Mesothelioma

06/25

02/26

HARMONIC, NCT05456256: A Study of LP-300 with Carboplatin and Pemetrexed in Never Smokers with Advanced Lung Adenocarcinoma

Recruiting

Japan, US, RoW

LP-300, Tavocept, BNP7787, Dimesna, Pemetrexed, Alimta, Pemfexy, Carboplatin, Paraplatin

Lantern Pharma Inc.

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

12/25

06/26

RAMP 203, NCT05074810: Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients

Recruiting

1/2

153

Europe, US

avutometinib and sotorasib, AMG 510, LUMAKRAS™, VS-6766, avutometinib and sotorasib and defactinib, VS-6063

Verastem, Inc., Amgen

Non Small Cell Lung Cancer, KRAS Activating Mutation

09/25

04/27

Jain, Mamta K

RESOLUTION, NCT04417257: Study of LAU-7b for the Treatment of COVID-19 Disease in Adults

Completed

2/3

125

Canada, US

LAU-7b, fenretinide, Placebo oral capsule

Laurent Pharmaceuticals Inc.

COVID-19 Disease

02/24

05/24

NCT03993106 / 2017-001828-22: A Study of sEphB4-HSA in Kaposi Sarcoma

Recruiting

sEphB4-HSA

Vasgene Therapeutics, Inc

Kaposi Sarcoma

12/24

06/25

Gruber, Joshua S

NCT05082610: A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors

Active, not recruiting

313

HMBD-002, Pembrolizumab

Hummingbird Bioscience, Merck Sharp & Dohme LLC

Cancer, Tumor, Solid, Nonsmall Cell Lung Cancer, Triple Negative Breast Cancer, Malignant Neoplasm, Metastatic Cancer, Advanced Solid Tumor

11/24

07/25

Smith, Carrie

NCT03926624: Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage

Recruiting

450

DFP-10917, Cytarabine, Azacitidine, Decitabine, Mitoxantrone, Etoposide, Fludarabine, Idarubicin, Venetoclax, Cladribine

Delta-Fly Pharma, Inc.

Leukemia, Myeloid, Acute

12/25

06/26

NCT03671044: A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients

Recruiting

657

US, RoW

Nanosomal Docetaxel Lipid Suspension (75 mg/m2), Nanosomal Docetaxel Lipid Suspension (100 mg/m2), Taxotere® (100 mg/m2)

Jina Pharmaceuticals Inc., Intas Pharmaceuticals, Ltd., Lambda Therapeutic Research Ltd.

Triple Negative Breast Cancer

05/25

12/25

NCT01954992: Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer

Recruiting

480

Glufosfamide, Fluorouracil, 5-FU

Eleison Pharmaceuticals LLC.

Metastatic Pancreatic Adenocarcinoma

06/26

12/26

BRIA-ABC, NCT06072612: Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

Recruiting

404

SV-BR-1-GM, Part of the Bria-IMT regimen, Cyclophosphamide, Interferon infiltration of the inoculation site, Retifanlimab, Treatment of Physician's Choice

BriaCell Therapeutics Corporation

Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm, Breast Cancer Metastatic, End Stage Cancer

01/26

06/26

NCT03899467: The Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPC

Completed

GT0918, proxalutamide, androgen receptor antagonist

Suzhou Kintor Pharmaceutical Inc,

Metastatic Castrate Resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

03/22

09/22

NCT06246110: A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC

Recruiting

EIK1001, Pembrolizumab, Paclitaxel, Pemetrexed, Carboplatin

Eikon Therapeutics

NSCLC

12/26

12/27

SGNLVA-005, NCT04032704 / 2019-001946-17: A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

Terminated

205

Europe, US, RoW

ladiratuzumab vedotin, SGN-LIV1A, pembrolizumab, Keytruda

Seagen Inc., Merck Sharp & Dohme LLC

11/23

Terminated

NovoTTF-200T, Pembrolizumab (MK-3475) 200 mg

NovoCure GmbH, Merck Sharp & Dohme LLC

Non-small Cell Lung Cancer

01/25

VIRO-25, NCT06463665: Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer

Recruiting

142

Genelux Corporation, Newsoara Biopharma Co., Ltd.

02/27

07/29

NCT06568692: A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer

Recruiting

PCS6422 and capecitabine, Capecitabine

Processa Pharmaceuticals

Breast Cancer, TNBC - Triple-Negative Breast Cancer, HER2-negative Breast Cancer

09/26

10/26

HARMONIC, NCT05456256: A Study of LP-300 with Carboplatin and Pemetrexed in Never Smokers with Advanced Lung Adenocarcinoma

Recruiting

Japan, US, RoW

LP-300, Tavocept, BNP7787, Dimesna, Pemetrexed, Alimta, Pemfexy, Carboplatin, Paraplatin

Lantern Pharma Inc.

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

12/25

06/26

A2A-005, NCT05403385: Study of Inupadenant (EOS100850) with Chemotherapy As Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer

Recruiting

186

Europe, Canada, US, RoW

inupadenant, EOS100850, Placebo, Carboplatin, Pemetrexed, Alimta

iTeos Therapeutics, iTeos Belgium SA

Metastatic NSCLC - Non-Small Cell Lung Cancer, Locally Advanced NSCLC - Non-Small Cell Lung Cancer

04/25

05/25

NCT05494697: Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC

Jan 2024 - Dec 2024 : Data readout for locally advanced pancreatic adenocarcinoma

Suspended

Rintatolimod, Ampligen, poly I : poly C12U

AIM ImmunoTech Inc., Amarex Clinical Research

Pancreatic Cancer

09/28

10/28

AVB500-PC-005, NCT04983407: Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic Adenocarcinoma

Terminated

1b/2

batiraxcept, AVB-S6-500, Nab paclitaxel, Abraxane, Gemcitabine

Aravive, Inc.

Pancreatic Adenocarcinoma

08/23

NCT05320198: Study of DISC-0974 in Participants with Myelofibrosis or Myelodysplastic Syndrome and Anemia

Recruiting

1/2

150

DISC-0974

Disc Medicine, Inc

Myelofibrosis; Anemia, Anemia, Myelofibrosis, Myelofibrosis Due to and Following Polycythemia Vera, Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Myelodysplastic Syndromes

09/26

INDP-D101, NCT05651022: Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors

Recruiting

1/2

120

Decoy20, Tislelizumab

Indaptus Therapeutics, Inc, Translational Drug Development

06/27

09/27

INX-315-01, NCT05735080: Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

Recruiting

1/2

150

US, RoW

INX-315, Fulvestrant, faslodex, Abemaciclib, Verzenio

Incyclix Bio

12/25

06/26

XTX301-01, NCT05684965: XTX301 in Patients with Advanced Solid Tumors

Recruiting

1/2

358

XTX301

Xilio Development, Inc.

Advanced Solid Tumor

02/27

NCT05622058: A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer

Terminated

Europe, US, RoW

ALRN-6924, TAC (doxorubicin 50 mg/m2; cyclophosphamide 500 mg/m2; docetaxel 75 mg/m2)

Aileron Therapeutics, Inc.

Prevention of Chemotherapy-induced Myelosuppression

02/23

NCT04215809 / 2020-002736-73: Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL

Recruiting

144

US, RoW

Lisaftoclax

Ascentage Pharma Group Inc.

CLL/SLL

10/25

06/27

KEYNOTE-A78, NCT03978689: A Phase 1 Study in Patients with HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma

Active, not recruiting

CUE-101, KEYTRUDA®, Pembrolizumab, Pembrolizumab

Cue Biopharma, Merck Sharp & Dohme LLC

Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Related Carcinoma

01/26

NCT04958434: Study of TST005 in Patients With Locally Advanced or Metastatic Solid Tumors

Terminated

TST005

Suzhou Transcenta Therapeutics Co., Ltd.

Locally Advanced or Metastatic Cancers, Metastatic Human Papillomavirus-Related Malignant Neoplasm

09/23

NCT06130722: First-in-Human, Phase I, Open-label, Multicenter, Dose Escalation Clinical Study

Recruiting

FL115

Suzhou Forlong Biotechnology Co.,Ltd,

Locally Advanced/Metastatic Solid Tumors

05/25

09/25

IO-108-CL-001, NCT05054348: First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors

Completed

IO-108, IO-108 + pembrolizumab combination therapy, IO-108 + Keytruda combination therapy, IO-108 + cemiplimab combination therapy, IO-108 + Libtayo combination therapy

Immune-Onc Therapeutics, Regeneron Pharmaceuticals

Solid Tumor, Adult

04/24

05/24

NKT3447-101, NCT06264921: A Study with NKT3447 for Adults with Advanced/Metastatic Solid Tumors

Active, not recruiting

NKT3447

NiKang Therapeutics, Inc.

11/25

03/27

NCT05600582: A Study of CodaLytic, an Intratumoral Oncolytic Virus, in Patients With Breast Cancer

Withdrawn

CodaLytic

Codagenix, Inc

Breast Neoplasms, Neoplasm Metastasis

09/24

01/25

NCT03556228: Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

Recruiting

VMD-928 300 mg Tablet (ongoing); 100 mg Capsule (complete)

VM Oncology, LLC

07/26

12/26

CUE-102-01, NCT05360680: A Phase 1 in Patients with HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers

Completed

CUE-102

Cue Biopharma

Colorectal Cancer, Gastric Cancer, Pancreatic Cancer, Ovarian Cancer

03/25

NCT05293912: SG2501 Safety Study in Subjects with Relapsed or Refractory Hematological Malignancies and Lymphoma.

Terminated

SG2501, Recombinant Anti-cluster of Differentiation 38(CD38)/47(CD47) Bispecific Antibody

Hangzhou Sumgen Biotech Co., Ltd.

Hematological Malignancy, Lymphoma

06/23

SGR-1505-101, NCT05544019: Study of SGR-1505 in Mature B-Cell Neoplasms

Recruiting

US, RoW

SGR-1505

Schrödinger, Inc.

03/26

NCT05627063: A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors

Recruiting

169

US, RoW

ABSK121-NX

Abbisko Therapeutics Co, Ltd

Solid Tumor

03/25

06/25

NCT05757492: Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors

Terminated

CHS-006 (anti-TIGIT), JS006, toripalimab (anti-PD-1), CHS-007, TAB001, JS001

Coherus Biosciences, Inc., Medpace, Inc., Shanghai Junshi Bioscience Co., Ltd.

Advanced Solid Tumor, Non-Small Cell Lung Cancer, Hepatocellular Carcinoma

07/24

ON-5001, NCT06022029: A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

Recruiting

168

US, RoW

ONM-501, Cemiplimab, Libtayo

OncoNano Medicine, Inc.

04/26

08/26

IGM-8444-001, NCT04553692: Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers

Terminated

272

Europe, US, RoW

IGM Biosciences, Inc.

Solid Tumor, Colorectal Cancer, Non Hodgkin Lymphoma, Sarcoma, Chondrosarcoma, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia

01/25

ELEPHAS-01, NCT05478538: Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform

Recruiting

N/A

200

Core Needle or Forceps Biopsy

Elephas, Beaufort CRO

Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer, NSCLC, Metastatic NSCLC - Non-Small Cell Lung Cancer

12/26

Creo, Ana L

HAMS-AB-01B, NCT06057454: R-5280 in Newly Diagnosed Patients with Type 1 Diabetes

Recruiting

R-5280, Placebo

Rise Therapeutics LLC

Type 1 Diabetes, Type 1 Diabetes (Juvenile Onset), Diabetes Mellitus, Type 1

05/25

09/25

palma, Ingrid

CBX-12-101, NCT04902872: Study of CBX-12 in Subjects with Advanced or Metastatic Refractory Solid Tumors

Active, not recruiting

1/2

130

CBX-12

Cybrexa Therapeutics

03/25

06/25

KEYNOTE-B47, NCT04130516: Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and with Pembrolizumab

Recruiting

1/2

200

LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER, Pembrolizumab - anti-PD-1 antibody, KEYTRUDA®, Pembrolizumab

Linnaeus Therapeutics, Inc., Merck Sharp & Dohme LLC

Solid Tumor, Adult

12/26

12/27

NCT04875806: A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors

Terminated

1/2

NC762

NextCure, Inc.

Advanced or Metastatic Solid Tumors, Ovarian Cancer, Non-small Cell Lung Cancer, Breast Cancer

01/24

ABOYA-119, NCT04905914: Study Of ATRN-119 In Patients With Advanced Solid Tumors

Recruiting

1/2

132

ATRN-119

Aprea Therapeutics

Advanced Solid Tumor

02/28

NCT05902988: A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

Recruiting

1/2

120

VLS-1488

Volastra Therapeutics, Inc.

12/25

06/26

ACR-368-201, NCT05548296: A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma

Recruiting

1/2

390

ACR-368, prexasertib, Gemcitabine, OncoSignature

Acrivon Therapeutics, GOG Foundation

Platinum-resistant Ovarian Cancer, Endometrial Adenocarcinoma, Urothelial Carcinoma

07/26

12/27

NCT04717375: Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors

Active, not recruiting

1/2

456

Europe, Canada, US, RoW

SAR444881, BND-22, Pembrolizumab, Cetuximab, Carboplatin, Pemetrexed

Sanofi

Cancer, Neoplasm

06/25

NCT04237649: KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors

Terminated

Europe, Canada, Japan, US, RoW

KAZ954, PDR001, NIR178, NZV930

Novartis Pharmaceuticals

Solid Tumors

09/23

QTX3034-001, NCT06227377: QTX3034 in Patients With KRAS G12D Mutation

Recruiting

250

QTX3034, Cetuximab

Quanta Therapeutics

Solid Tumors

04/27

NCT05082610: A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors

Active, not recruiting

313

HMBD-002, Pembrolizumab

Hummingbird Bioscience, Merck Sharp & Dohme LLC

Cancer, Tumor, Solid, Nonsmall Cell Lung Cancer, Triple Negative Breast Cancer, Malignant Neoplasm, Metastatic Cancer, Advanced Solid Tumor

11/24

07/25

CPO-100-US-101, NCT04931823: Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors

Active, not recruiting

126

CPO-100, DTX-HSA

Conjupro Biotherapeutics, Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Solid Tumor

03/25

KEYNOTE-F86, NCT05787587: A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

Recruiting

216

IDE-161, Pembrolizumab, KEYTRUDA®

IDEAYA Biosciences, Merck Sharp & Dohme LLC

Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer, Endometrial Cancer, Colorectal Cancer, Head and Neck Cancers, Nsclc

10/26

05/27

NCT05702424: Evaluation of IGM-7354 in Adults With Relapsed and/or Refractory Cancer

Completed

IGM-7354

IGM Biosciences, Inc.

Solid Tumor

05/24

NCT05753722: A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies

Recruiting

270

PRTH-101, Pembrolizumab

Incendia Therapeutics

Advanced or Metastatic Solid Tumors

09/27

ELVCAP-002-01, NCT05980416: Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2

Recruiting

120

Japan, US, RoW

EO-3021

Elevation Oncology

Pancreas Neoplasm, Stomach Neoplasm, Gastrointestinal Neoplasms, Digestive System Neoplasm, Neoplasms by Site, Neoplasms

09/28

12/28

Brinkman, Janet

HAMS-AB-01B, NCT06057454: R-5280 in Newly Diagnosed Patients with Type 1 Diabetes

Recruiting

R-5280, Placebo

Rise Therapeutics LLC

Type 1 Diabetes, Type 1 Diabetes (Juvenile Onset), Diabetes Mellitus, Type 1

05/25

09/25

Download Options



	Diseases Companies Products Productz Mechanisms of Action Sites